Inactive Instrument

GreenLight Biosciences Holdings

Equities

GRNA

US39536G1058

Biotechnology & Medical Research

GreenLight Biosciences Holdings Reports Earnings Results for the First Quarter Ended March 31, 2023

May 11, 2023 at 12:20 pm

GreenLight Biosciences Holdings reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 3.82 million compared to USD 0.257 million a year ago. Net loss was USD 28.47 million compared to USD 38.21 million a year ago.

Basic loss per share from continuing operations was USD 0.19 compared to USD 0.34 a year ago.

Latest news about GreenLight Biosciences Holdings

Greenlight Biosciences Holdings Announces Resignation of Directors	24/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite Index	24/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from S&P TMI Index	24/07/23	CI
A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings from stockholders.	23/07/23	CI
GreenLight Biosciences Holdings announced that it has received $67.075 million in funding from a group of investors	23/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Biotechnology Index	19/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell Small Cap Comp Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2000 Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000 Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell Small Cap Completeness Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2500 Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2000 Dynamic Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000E Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2000 Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2500 Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000 Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000E Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from S&P Global BMI Index	19/06/23	CI
GreenLight Biosciences Holdings announced that it expects to receive $115 million in funding from a group of investors	28/05/23	CI
GreenLight Biosciences Holdings Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC agreed to acquire GreenLight Biosciences Holdings from stockholders for $42.1 million.	29/03/23	CI
GreenLight Biosciences Holdings Auditor Raises 'Going Concern' Doubt	27/03/23	CI
Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccine	02/02/23	CI
Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine Candidate	01/02/23	CI
Greenlight Biosciences and Epivax Therapeutics Signs Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines	09/01/23	CI

Chart GreenLight Biosciences Holdings

Duration

Period

More charts

Company Profile

GreenLight Biosciences Holdings, PBC is a pre-commercial stage biotechnology company. The Company has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The Company's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. It has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The Company's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.10%	47.96B
IQVIA HOLDINGS INC.	+0.67%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.33%	31.6B
ICON PUBLIC LIMITED COMPANY	+20.72%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.06%	14.56B
MEDPACE HOLDINGS, INC.	+44.93%	14.14B
BIO-TECHNE CORPORATION	+2.63%	12.58B

Other Biotechnology & Medical Research